CD26 Antibodies

Santa Cruz Biotechnology features a diverse variety of CD26 monoclonal antibodies for research focused on understanding this important protein. CD26 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD26, also known as dipeptidyl peptidase IV (DPP-IV), plays a crucial role in immune regulation, cell signaling, and metabolism. CD26 is involved in the activation and inactivation of various bioactive peptides, influencing processes such as glucose homeostasis and immune responses. The study of CD26 has revealed significant implications in various diseases, including diabetes and cancer. CD26 research continues to uncover new insights into cellular mechanisms and potential therapeutic approaches. Ongoing investigations of CD26 contribute to the advancement of treatment strategies for multiple conditions. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of CD26 and its therapeutic applications.